10-Q: SCYNEXIS Q3 Loss Widens Amid GSK Deal Shift, SCY-247 Progress

SCYNEXIS reported a wider net loss in Q3 2025, driven by reduced license revenue, while advancing its SCY-247 antifungal program and securing a $24.8 million payment from GSK following the termination of the MARIO study.

Summary

• SCYNEXIS reported a net loss of $20.867 million for the nine months ended September 30, 2025, an increase from $16.855 million in the same period of 2024.
• License agreement revenue decreased by 29.4% to $1.955 million for the nine months ended September 30, 2025, compared to $2.769 million in the prior year.
• Research and development expenses decreased by 19.7% to $17.735 million, primarily due to lower chemistry, manufacturing, and controls (CMC) and clinical expenses, partially offset by increased preclinical costs for SCY-247.
• Selling, general and administrative expenses increased by 11.0% to $10.815 million, driven by higher business development and salary expenses.
• The company received a Nasdaq notification on June 20, 2025, regarding non-compliance with the $1.00 minimum bid price rule, with a compliance date of December 17, 2025.
• SCYNEXIS and GSK entered into a binding memorandum of understanding in October 2025 to terminate the MARIO study, resulting in a one-time payment of $24.8 million to SCYNEXIS.
• The Phase 1 study of oral SCY-247 in healthy subjects demonstrated good safety, tolerability, and dose-proportional pharmacokinetics, with efficacious exposure targets met in preclinical models.
• Legal proceedings, including a securities class action and consolidated shareholder derivative action, were dismissed in August and October 2025, respectively.

Sentiment

Score: 4

Explanation: The filing presents a mixed bag of operational progress and financial challenges. Positive clinical data for SCY-247 and the $24.8 million payment from GSK are strong points. However, the increased net loss, higher cash burn, and the Nasdaq minimum bid price non-compliance are significant concerns that weigh down overall sentiment.

Positives

• SCY-247 Phase 1 study for oral formulation showed positive results, demonstrating good safety, tolerability, and dose-proportional pharmacokinetics, with efficacious exposure targets met in preclinical models.
• The company will receive one-time payments totaling $24.8 million from GSK following the termination of the MARIO study, providing a significant cash inflow.
• The securities class action and consolidated shareholder derivative action lawsuits were dismissed, removing significant legal overhangs.
• GSK reiterated its commitment to continued collaboration on other aspects of the GSK License Agreement, including commercialization of BREXAFEMME for VVC and rVVC.

Negatives

• Net loss for the nine months ended September 30, 2025, increased to $20.867 million from $16.855 million in the prior year, indicating worsening profitability.
• License agreement revenue decreased by 29.4% to $1.955 million for the nine months ended September 30, 2025.
• Net cash used in operating activities significantly increased to $23.684 million for the nine months ended September 30, 2025, compared to $14.102 million in the prior year, indicating higher cash burn.
• Cash and cash equivalents and investments decreased to $37.9 million as of September 30, 2025, from $75.1 million at December 31, 2024.
• The company received a Nasdaq notification for failing to meet the $1.00 minimum bid price requirement, posing a risk of delisting if compliance is not regained by December 17, 2025.
• The MARIO study was terminated, meaning no additional development milestone payments specifically associated with this study will be received from GSK.

Risks

• The company's liquidity could be materially affected by its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding.
• Costs associated with new or existing strategic alliances, or licensing and collaboration arrangements, could impact liquidity.
• Negative regulatory events or unanticipated costs related to the development of SCY-247 and ibrexafungerp pose financial risks.
• The ability to successfully achieve the regulatory and commercial milestones under the GSK License Agreement is crucial for future revenue.
• Failure to regain compliance with the Nasdaq minimum bid price rule could lead to delisting of the company's common stock.
• The successful development of product candidates is highly uncertain, and the nature, timing, or costs required to complete development cannot be reasonably estimated.

Future Outlook

The company intends to initiate a Phase 1 study of the intravenous formulation of SCY-247 in the first quarter of 2026, with a clinical proof-of-concept Phase 2 study in patients with invasive candidiasis anticipated in 2026. Subsequent development stages are expected to support an invasive candidiasis treatment indication and evaluate SCY-247 for prevention of invasive fungal diseases in high-risk patients. GSK anticipates initiating regulatory interactions with the FDA in 2026 to discuss the relaunch of BREXAFEMME for VVC and rVVC in the U.S. market, following the transfer of the BREXAFEMME NDA to GSK by the end of 2025. The company expects to incur significant research and development and selling, general and administrative expenses and will need additional capital to fund future operations.

Management Comments

• We remain committed to developing novel antifungal solutions to the rising threat of deadly fungal infections including invasive candidiasis for which there are limited treatment options and significant concerns for emergence of resistances.
• We believe that SCY-247, if approved, has the potential to address significant gaps with commercially available therapies in invasive candidiasis and prevention of invasive fungal infections in patients at high risk.
• The safety, tolerability, and pharmacokinetic profile observed in the Phase 1 study support the continued clinical development of SCY-247.
• We believe our capital resources are sufficient to fund our on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements.

Industry Context

SCYNEXIS operates in the biotechnology sector, specifically focusing on antifungal treatments, an area highlighted by the World Health Organization for its unmet needs due to rising drug resistance. The development of novel broad-spectrum agents like fungerps (ibrexafungerp and SCY-247) addresses critical gaps in current therapies, particularly for multidrug-resistant strains and invasive fungal infections where mortality remains high. The company's strategy to develop both oral and IV formulations for SCY-247 positions it to potentially offer flexible treatment options, a key advantage in managing chronic and acute infections. The collaboration with GSK for BREXAFEMME commercialization leverages a larger pharmaceutical partner's resources, while the termination of the MARIO study allows SCYNEXIS to focus its resources on SCY-247, which it fully owns.

Comparison to Industry Standards

• SCY-247's demonstrated potent activity against azole-resistant and most echinocandin-resistant Candida strains, including Candida auris and C. glabrata, positions it favorably against existing antifungal treatments which face increasing resistance concerns.
• The fungicidal capabilities of SCY-247 against the Candida genus contrast with azoles, which are fungistatic, potentially offering a more definitive treatment outcome for invasive candidiasis.
• SCY-247's low risk of drug-drug interactions via CYP inhibition, based on available data, could provide a significant advantage over oral azoles for antifungal prophylaxis in immunocompromised patients receiving chemotherapy or transplants, where concurrent medication interactions are a major concern.

Legal Proceedings

• A securities class action filed on November 7, 2023, alleging misstatements regarding manufacturing controls and related risks, was dismissed with prejudice on August 29, 2025.
• Consolidated shareholder derivative complaints filed on May 1, 2024, and June 4, 2024, asserting related claims, were dismissed without prejudice on October 15, 2025.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and the risk of delisting from Nasdaq due to the minimum bid price non-compliance.
• Employees in R&D may see shifts in focus and resources towards SCY-247 development following the MARIO study termination.
• Customers (patients) could benefit from the continued development of SCY-247 as a novel antifungal treatment, particularly for resistant infections, and the potential relaunch of BREXAFEMME.
• GSK's commitment to BREXAFEMME commercialization and the $24.8 million payment indicate a continued, albeit modified, partnership.
• Creditors (if any future debt financing) would be impacted by the company's liquidity and ability to generate future revenue.

Next Steps

• Initiate a Phase 1 study of the intravenous formulation of SCY-247 in the first quarter of 2026.
• Initiate a clinical proof-of-concept Phase 2 study for SCY-247 in patients with invasive candidiasis in 2026.
• Conduct subsequent development stages for SCY-247 to support an invasive candidiasis treatment indication and evaluate for prevention of invasive fungal diseases.
• Complete the transfer of the BREXAFEMME NDA to GSK by the end of 2025.
• GSK to initiate regulatory interactions with the FDA in 2026 to discuss the relaunch of BREXAFEMME for VVC and rVVC in the U.S. market.
• Regain compliance with the Nasdaq minimum bid price rule by December 17, 2025.

Key Dates

Recommendation

The filing presents a mixed outlook. While the positive Phase 1 data for SCY-247 and the $24.8 million payment from GSK are favorable, the increased net loss, higher cash burn, and the Nasdaq minimum bid price non-compliance are significant concerns. The company's need for additional capital and the inherent risks of drug development add uncertainty. For existing investors, holding the stock to monitor SCY-247's progress and Nasdaq compliance seems prudent, given the potential upside of the pipeline balanced against current financial pressures. New investors might wait for clearer financial stability and resolution of the Nasdaq issue.

Keywords

SCYNEXIS, SCYX, 10-Q, biotechnology, antifungal, SCY-247, BREXAFEMME, ibrexafungerp, GSK, Nasdaq, clinical trials, drug development, invasive candidiasis, vulvovaginal candidiasis, financial results